Status:
COMPLETED
HIV Persistence in Lymph Node and Peripheral Blood
Lead Sponsor:
University of Melbourne
Collaborating Sponsors:
amfAR, The Foundation for AIDS Research
University of California, San Francisco
Conditions:
HIV-1-infection
Eligibility:
All Genders
18+ years
Brief Summary
The aim of this project is to determine whether latent HIV is enriched in cells expressing certain proteins (receptors) on their surface and whether it is possible to eliminate these cells through the...
Detailed Description
Combination antiretroviral therapy (ART) has significantly improved the immune function of HIV infected individuals and has transformed a fatal disease into a chronic infection for those with access t...
Eligibility Criteria
Inclusion
- Written Informed Consent
- Willing to undergo leukapheresis and lymph node biopsy
- Documented HIV-1 infection (antibody positive or detectable plasma HIV-1 RNA)
- Receiving combination ART
- HIV RNA \< 50 copies/mL for \> 3 years (Episodes of a single HIV plasma RNA 50-500 copies/mL will not exclude participation if the subsequent HIV plasma RNA was \<50 copies/mL)
Exclusion
- Unwillingness to follow protocol requirements
- Contraindications to LN biopsy or leukapheresis
- Current skin infection of inguinal area
- Known current lower extremity, gastrointestinal or genitourinary infection
Key Trial Info
Start Date :
January 2 2017
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
October 17 2018
Estimated Enrollment :
8 Patients enrolled
Trial Details
Trial ID
NCT03426189
Start Date
January 2 2017
End Date
October 17 2018
Last Update
June 23 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Alfred Hospital
Melbourne, Victoria, Australia, 3181